400 µg of MBX 2109 once-weekly by subcutaneous injection + 200-1600 µg of MBX 2109 once-weekly by subcutaneous injection
Phase 2Active 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hypoparathyroidism
Conditions
Hypoparathyroidism
Trial Timeline
Oct 31, 2024 → May 27, 2027
NCT ID
NCT06531941About 400 µg of MBX 2109 once-weekly by subcutaneous injection + 200-1600 µg of MBX 2109 once-weekly by subcutaneous injection
400 µg of MBX 2109 once-weekly by subcutaneous injection + 200-1600 µg of MBX 2109 once-weekly by subcutaneous injection is a phase 2 stage product being developed by MBX Biosciences for Hypoparathyroidism. The current trial status is active. This product is registered under clinical trial identifier NCT06531941. Target conditions include Hypoparathyroidism.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06531941 | Phase 2 | Active |
Competing Products
9 competing products in Hypoparathyroidism
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| MBX 2109 | MBX Biosciences | Phase 2 | 47 |
| PCO371 + Placebo | Chugai Pharmaceutical | Phase 1 | 33 |
| recombinant human somatotropin | Eli Lilly | Pre-clinical | 23 |
| Palopegteriparatide | Ascendis Pharma | Pre-clinical | 20 |
| Palopegteriparatide (TransCon PTH) | Ascendis Pharma | Pre-clinical | 20 |
| Palopegteriparatide | Ascendis Pharma | Pre-clinical | 20 |
| EnteraBio's Oral Parathyroid Hormone (1-34) | Entera Bio | Phase 2 | 44 |
| EBP05 + Forteo 0.02 mg + EBP11 + EBP22 + EBP11-F2 + EBP11-F4 + EBP11-F1 + EBP11-F5 | Entera Bio | Phase 1 | 25 |
| EB612 (EBP05) + NATPARA/NATPAR | Entera Bio | Phase 2 | 44 |